GSIs have shown promise in treating various types of cancers, including breast cancer, leukemia, lung cancer, and glioblastoma. The effectiveness of GSIs in these cancers is often linked to the aberrant activation of the Notch signaling pathway, which can promote oncogenesis and resistance to conventional therapies.
